Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Free fatty acid receptor (FFAR) family consists of G protein-coupled receptors (GPCRs) that act as nutrient sensors by responding to non-esterified fatty acids of various chain lengths. This family includes FFAR1 (GPR40) and FFAR4 (GPR120), which are activated by medium- and long-chain fatty acids to promote insulin secretion and anti-inflammatory signaling, as well as FFAR2 (GPR43) and FFAR3 (GPR41), which sense short-chain fatty acids produced by gut microbiota. These receptors play crucial roles in maintaining metabolic homeostasis and regulating immune responses, making them significant therapeutic targets for metabolic and inflammatory diseases. FFAR1, in particular, has been extensively studied for its ability to enhance glucose-dependent insulin secretion without the high risk of hypoglycemia associated with other antidiabetic agents. However, drug development in this space has faced challenges, most notably concerns regarding hepatotoxicity that led to the termination of clinical programs for several early candidates.
Agonism, Allosteric modulation
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Free fatty acid receptor (FFAR) (FFAR).